Mike Woolcock serves as senior vice president of Apobiologix, a leader in biologic innovation and biosimilar development. Mike has more than 30 years of experience managing commercialization of pharmaceutical and biotech products. He has worked in small and large pharmaceutical companies as well as start-up and large biotechnology companies. In addition, to his commercial experience Mike has spent time in R&D roles within the industry globally. He provides the company with valuable insight into the evolving biosimilar landscape. Tapping into his deep understanding of development and commercialization, he offers strategic input to support commercial planning for the biosimilars of interest to Apobiologix.
Mike has been a member of Apotex for over ten years. Prior to joining Apotex, Mike held positions with Procter & Gamble, Cortech and Amgen. Mike earned his BSc in Biochemistry and Genetics from La Trobe University, Melbourne, Australia.
Nirmesh has over 15 years of experience in the pharmaceutical industry working in both the commercial and medical affairs divisions. He has been with Apotex since 2015 and he previously worked for IQVIA as the Director of Medical Affairs. Nirmesh has also worked for Johnson & Johnson and Sunovion. He received his Doctor of Pharmacy at the University of South Carolina.
Chris has 28 years of commercial experience in pharmaceuticals and medical device. He is currently focused on market access and government relations for Apobiologix' biosimilars portfolio. He holds the role of Vice Chair for the Biosimilars Market Access Committee. Prior to his current role, Chris was Director of Business Development and Strategic Marketing during which he worked with global partners to grow Apobiologix' future product portfolio. He joined Apotex in 2009 managing the commercial portfolio and global product selection. Before transitioning to biosimilars, he was the Director of Apotex's specialty portfolio.
Chris studied Business Administration at Wilfrid Laurier University. He started his pharmaceutical career at IMS where he held domestic and international commercial roles including 3 years with IMS' Global Services division based in London, UK. Chris gained brand healthcare marketing and sales experience during his time at Bayer and Zimmer.
For market access and government relations inquiries, please contact Chris
Joe has been with Apobiologix since 2012. With 20 years of experience in R&D and commercial operations, he has been involved in the development, submission, manufacture and supply of commercially marketed biologic drugs.
Joe oversees the day-to-day operations of Apobiologix and leads a team that develops processes and systems to coordinate assessment of pipeline products, product lifecycle management, commercial supply and business analytics.
Joe earned a B.Sc. from McMaster University and an MBA from Schulich School of Business.
Rob Butler serves as Director, Sales and Marketing at Apobiologix, a leader in biologic innovation and biosimilar development. Rob has more than 30 years of experience working in both the pharmaceutical and biotechnology sectors in several different roles including sales, clinical research, marketing and sales management. In the last 23 years Rob, has worked exclusively in the area of Oncology and brings this knowledge and experience to Apobiologix.
Garry Egan has served as Marketing Director of Apobiologix, since 2021.Garry has over 35 years of experience managing the commercialization and launch of pharmaceutical and biologic products. Garry has held leadership roles in marketing, sales, market access, regulatory and government affairs. He has led cross functional teams across many therapeutic areas including Oncology, Hematology, Rheumatology, Dermatology, Cardiology, Nephrology, Gastroenterology, Neurology, and Immunology. His insights into the Canadian treatment landscape have been instrumental in the successful launch and ongoing commercialization of numerous biologics and biosimilar products.
Prior to joining Apobiologix, Garry held leadership positions with Amgen, Janssen and Glaxo. Garry earned his Honours B.Sc. from the University of Toronto, Specializing in Pharmacology and Physiology.